CD274 and ovarian cancer: The phase I study evaluating durvalumab (anti-PD-L1 antibody) in combination with olaparib in 12 patients (10 with ovarian cancer and two with TNBC) with 11 of which were BRCAwt, two women achieved PR and eight women had stable disease, achieving an 83% DCR (45).